EXPLORE!

Aprocitentan Demonstrates Safety and Efficacy in CKD Patients with Resistant Hypertension

  643 Views

#Cardiology  #Nephrology 

Emedinexus    10 January 2024

A recent subgroup analysis of the pivotal trial, PRECISION, revealed that aprocitentan (APRO) treatment is safe and effective for patients with stage 3 or 4 chronic kidney disease (CKD). Aprocitentan, currently under review by the Food and Drug Administration (FDA), is a novel agent designed to lower blood pressure in individuals with treatment-resistant hypertension.

 

Chronic kidney disease often complicates hypertension management, posing challenges in controlling blood pressure effectively. The phase 3 PRECISION trial demonstrated significant reductions in blood pressure with aprocitentan at doses of 12.5mg and 25mg once daily compared to placebo in patients with resistant hypertension.

 

In this subgroup analysis focusing on CKD patients enrolled in PRECISION, participants exhibited uncontrolled systolic blood pressure (SBP) despite using three or more antihypertensive drugs. The analysis included individuals with an estimated glomerular filtration rate (eGFR) of 15 to <60mL/min/1.73m2.

 

The findings showed that both doses of APRO led to a more substantial reduction in blood pressure from baseline to week four compared to placebo, as confirmed by ambulatory blood pressure monitoring (ABPM). Edema or fluid retention was observed in 18% and 24% of patients receiving APRO at 12.5mg and 25mg, respectively, compared to 2% with placebo. The rate increased to 34% in subjects exposed to APRO 25mg throughout the trial. Of those experiencing edema, 55% were treated with diuretics (90% loop diuretics), and two patients discontinued treatment due to this event.

 

Lastly, five patients receiving APRO 25mg and one receiving a placebo had heart failure leading to hospitalization; however, all but one had a history of heart disease.

 

(Source:https://medicaldialogues.in/nephrology/news/aprocitentan-effective-for-bp-lowering-in-patients-with-ckd-and-resistant-hypertension-122383 )

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.